Skip to content
Erudio Health
menu
Clinical trial · no report yet · Phase 2

NEST-1

Combination Immunotherapy in Colorectal Cancer

  • NCT05571293 ↗
  • Completed
  • Weill Medical College of Cornell University
  • 55 commentary sources found
  • Deep

We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.

Commentary we found

Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.

ChannelFound
X threads38
YouTube8
Podcasts8
X videos1

The trial

ClinicalTrials.gov
Official title
Novel Exploratory Study to Test Combination of Botensilimab and Balstilimab Immunotherapy in Resectable Colorectal Cancer Patients
Phase
Phase 2
Status
Completed
Conditions
Colorectal Neoplasms
Interventions
Botensilimab; Balstilimab
Arms
  • Cohort A: Botensilimab and balstilimab (bot/bal) · Experimental
  • Cohort B: · Experimental
  • Cohort C: · Experimental
Enrollment
26
Primary outcomes
  • Cohort A and B: Pathological Overall Response (pOR) Rate Determined by Analysis of Tissue Resected During Surgery Reported by Cohort
  • Cohort A: Number of Participants Who Experience Potentially Treatment-related SAEs According to the Common Terminology Criteria for Adverse Events (CTCAE) v5.0 at 90 Days Following the Last Treatment With Balstilimab or Botensilimab
  • Cohort A: Number of Participants Who Experience Treatment-related Complications Leading to Delays of 12 Weeks or More in Surgery After Treatment Initiation (Day 0)
  • Cohort C: Composite Rate of Clinical Complete Response or Major Pathological Response at 6 Months
Sponsor
Weill Medical College of Cornell University with Agenus Inc.
Start
Mar 17, 2023
Primary completion
Nov 14, 2024
Results posted
Yes
Registry record
NCT05571293 · updated Oct 9, 2026